Skip to Content


In the US, Tarceva (erlotinib systemic) is a member of the drug class EGFR inhibitors and is used to treat Non-Small Cell Lung Cancer and Pancreatic Cancer.

US matches:

UK matches:

Ingredient matches for Tarceva


Erlotinib is reported as an ingredient of Tarceva in the following countries:

  • Colombia
  • Georgia
  • Hong Kong
  • Israel
  • Lebanon
  • Philippines
  • Turkey
  • Vietnam

Erlotinib hydrochloride (a derivative of Erlotinib) is reported as an ingredient of Tarceva in the following countries:

  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belgium
  • Bosnia & Herzegowina
  • Canada
  • Chile
  • China
  • Croatia (Hrvatska)
  • Czech Republic
  • Denmark
  • Ecuador
  • Egypt
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Indonesia
  • Ireland
  • Italy
  • Japan
  • Lithuania
  • Mexico
  • Moldova
  • Myanmar
  • Netherlands
  • New Zealand
  • Norway
  • Oman
  • Poland
  • Portugal
  • Romania
  • Serbia
  • South Africa
  • Spain
  • Sweden
  • Taiwan
  • Thailand
  • United Kingdom
  • United States
  • Uruguay

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.